Mitapivat (Aqvesme)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Transfusion-Dependent Beta Thalassemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Transfusion-Dependent Beta Thalassemia
Other / comorbidity

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Transfusion-Dependent Beta Thalassemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Mitapivat (Aqvesme): this drugApprovedSmall moleculePyruvate kinasePartial signal
NCT04770779: Transfusion reduction response in the double-blind period (baseline through Week 48), mitapivat vs placebo: 30.4% vs 12.6%, common risk difference 17.6 percentage points (95% CI 8.0 to 27.2), p=0.0003 (CT.gov posted results).
NCT04770753: Hemoglobin response from Week 12 through Week 24 in the double-blind period, mitapivat vs placebo: 42.3% vs 1.6%, difference 40.9 percentage points (95% CI 32.0 to 49.8), p<0.0001 (CT.gov posted results).
Exagamglogene Autotemcel (Casgevy)ApprovedGene therapy / editingBCL11A erythroid enhancer (gene editing)not yet gradedNo reviewed efficacy summary in this indication
Etavopivat
Phase 3(overall)
—Pyruvate kinase
not yet graded(overall)
No reviewed efficacy summary in this indication
Mitapivat (Pyrukynd)Phase 3Small moleculePyruvate kinasenot yet gradedNo reviewed efficacy summary in this indication
Renizgamglogene AutogedtemcelDiscontinuedGene or cell therapy (subtype unspecified)HBG1/HBG2 promotersnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.